NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $18.86 +0.14 (+0.75%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.70▼$18.9650-Day Range$17.11▼$20.9952-Week Range$5.63▼$26.35Volume71,240 shsAverage Volume207,359 shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$33.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NewAmsterdam Pharma alerts: Email Address NewAmsterdam Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.3% Upside$33.25 Price TargetShort InterestHealthy0.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 4 Articles This WeekInsider TradingAcquiring Shares$86,300 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.52) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.76 out of 5 starsMedical Sector222nd out of 936 stocksPharmaceutical Preparations Industry96th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 2 research reports in the past 90 days.Read more about NewAmsterdam Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.43% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NewAmsterdam Pharma has recently decreased by 22.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAMS. Previous Next 2.5 News and Social Media Coverage News SentimentNewAmsterdam Pharma has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NewAmsterdam Pharma this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,300.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.50% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($2.52) to ($1.60) per share.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NewAmsterdam Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About NewAmsterdam Pharma Stock (NASDAQ:NAMS)NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Read More NAMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAMS Stock News HeadlinesJuly 26 at 4:01 PM | globenewswire.comNewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024July 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 8, 2024 | globenewswire.comNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk FactorsJuly 5, 2024 | seekingalpha.comNewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year PeriodJuly 3, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | finance.yahoo.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 21, 2024 | finance.yahoo.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsMay 17, 2024 | investing.comNewAmsterdam Pharma stock initiated with Buy rating by TD CowenMay 17, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)May 16, 2024 | msn.comTD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationMay 10, 2024 | finance.yahoo.comNewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)May 9, 2024 | globenewswire.comNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsMay 3, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | finance.yahoo.comNewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024April 30, 2024 | bloomberg.comOzempic Maker Novo Nordisk Has Denmark’s Economy HookedSee More Headlines Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAMS CUSIPN/A CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$33.25 High Stock Price Target$37.00 Low Stock Price Target$30.00 Potential Upside/Downside+76.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.17 Quick Ratio8.17 Sales & Book Value Annual Sales$6.86 million Price / Sales247.30 Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book5.39Miscellaneous Outstanding Shares89,977,000Free Float72,431,000Market Cap$1.70 billion OptionableOptionable Beta0.01 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Michael Harvey Davidson FACC (Age 68)Facp., M.D., CEO, President, Executive Board Member & Director Comp: $882kDr. Johannes Jacob Pieter Kastelein FESC (Age 70)M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director Comp: $677.76kMr. Mayur Amrat Somaiya (Age 51)Chief Financial Officer Comp: $130.58kMr. Douglas F. Kling (Age 51)Chief Operating Officer Mr. Jim JacobsonChief Legal Officer & SecretaryDr. Marc Ditmarsch M.D. (Age 57)Chief Development Officer Dr. Sheng Cui Ph.D.VP & Head of Chemistry Manufacturing and Controls (CMC)Ms. Annie NeildVP & Head of Regulatory AffairsMr. William Jones Jr. (Age 60)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANKrystal BiotechNASDAQ:KRYSOrganon & Co.NYSE:OGNApellis PharmaceuticalsNASDAQ:APLSAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Bought 10,123 shares on 7/12/2024Ownership: 0.011%Michael H DavidsonBought 5,000 shares on 6/20/2024Total: $86,300.00 ($17.26/share)Opaleye Management Inc.Bought 50,000 shares on 5/29/2024Ownership: 0.351%Artal Group S.A.Bought 800,000 shares on 5/17/2024Ownership: 0.896%Janus Henderson Group PLCBought 636,231 shares on 5/16/2024Ownership: 0.713%View All Insider TransactionsView All Institutional Transactions NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $11.17 on January 1st, 2024. Since then, NAMS stock has increased by 68.8% and is now trading at $18.86. View the best growth stocks for 2024 here. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma (NASDAQ:NAMS) posted its earnings results on Wednesday, May, 8th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.08. The business had revenue of $1.40 million for the quarter, compared to analysts' expectations of $2.95 million. Who are NewAmsterdam Pharma's major shareholders? Top institutional investors of NewAmsterdam Pharma include Rosalind Advisors Inc. (0.01%). Insiders that own company stock include James N Topper, Michael H Davidson, Louis G Lange and Johannes Jacob Piete Kastelein. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NAMS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
